Adolfo G Mauro
Overview
Explore the profile of Adolfo G Mauro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
994
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hu X, Li L, Nkwocha J, Kmieciak M, Shang S, Cowart L, et al.
Signal Transduct Target Ther
. 2025 Feb;
10(1):50.
PMID: 39924517
The importance of MCL-1 in leukemogenesis has prompted development of MCL-1 antagonists e.g., S63845, MIK665. However, their effectiveness in acute myeloid leukemia (AML) is limited by compensatory MCL-1 accumulation via...
2.
Kovilakath A, Mauro A, Valentine Y, Raucci F, Jamil M, Carter C, et al.
Circulation
. 2024 Apr;
150(8):622-641.
PMID: 38660786
Background: Dysregulated metabolism of bioactive sphingolipids, including ceramides and sphingosine-1-phosphate, has been implicated in cardiovascular disease, although the specific species, disease contexts, and cellular roles are not completely understood. Sphingolipids...
3.
Salloum F, Tocchetti C, Ameri P, Ardehali H, Asnani A, de Boer R, et al.
JACC CardioOncol
. 2024 Jan;
5(6):715-731.
PMID: 38205010
Despite improvements in cancer survival, cancer therapy-related cardiovascular toxicity has risen to become a prominent clinical challenge. This has led to the growth of the burgeoning field of cardio-oncology, which...
4.
Mauro A, Yazbeck V, Salloum F
JACC CardioOncol
. 2022 Nov;
4(4):549-551.
PMID: 36444230
No abstract available.
5.
Mauro A, Mezzaroma E, Toldo S, Melendez G, Franco R, Lesnefsky E, et al.
Transl Res
. 2022 Aug;
252:9-20.
PMID: 35948198
Despite significant advances and the continuous development of novel, effective therapies to treat a variety of malignancies, cancer therapy-induced cardiotoxicity has been identified as a prominent cause of morbidity and...
6.
Mauro A, Hunter K, Salloum F
Adv Cancer Res
. 2022 Jul;
155:167-214.
PMID: 35779874
The quest of defeating cancer and improving prognosis in survivors has generated remarkable strides forward in research and have advanced the development of new antineoplastic therapies. These achievements, combined with...
7.
Devarakonda T, Valle Raleigh J, Mauro A, Lambert J, Cowart L, Salloum F
Sci Rep
. 2022 May;
12(1):8897.
PMID: 35614179
Relaxin is a pleiotropic hormone demonstrated to confer cardioprotection in animal models of myocardial infarction and ischemic heart failure by modulating inflammation, fibrosis and arrhythmogenesis. Several of these pathways in...
8.
Devarakonda T, Mauro A, Cain C, Das A, Salloum F
JACC Basic Transl Sci
. 2022 Feb;
7(1):53-63.
PMID: 35128209
Relaxin is a pleiotropic hormone shown to confer cardioprotection in several preclinical models of cardiac ischemia-reperfusion injury. In the present study, the effects of up-regulating relaxin family peptide receptor 1...
9.
Narayan P, Trikantzopoulos E, Mezzaroma E, Mauro A, Vohra H, Abbate A, et al.
Cytokine
. 2022 Jan;
151:155811.
PMID: 35091314
Background: Aging is associated with metabolic and structural changes causing heart failure with preserved ejection fraction (HFpEF). Interleukin-1 (IL-1) is a pro-inflammatory cytokine involved in aging-related inflammation. Objective: We sought...
10.
Quader M, Cholyway R, Wickramaratne N, Akande O, Mangino M, Mezzaroma E, et al.
Animal Model Exp Med
. 2021 Sep;
4(3):283-296.
PMID: 34557655
Heart transplantation is a lifesaving procedure, which is limited by the availability of donor hearts. Using hearts from donors after circulatory death, which have sustained global ischemia, requires thorough studies...